87 related articles for article (PubMed ID: 18045059)
1. Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.
Godeny MD; Sayeski PP
Anticancer Agents Med Chem; 2007 Nov; 7(6):643-50. PubMed ID: 18045059
[TBL] [Abstract][Full Text] [Related]
2. Jak2 tyrosine kinase: a true jak of all trades?
Sandberg EM; Wallace TA; Godeny MD; VonDerLinden D; Sayeski PP
Cell Biochem Biophys; 2004; 41(2):207-32. PubMed ID: 15475610
[TBL] [Abstract][Full Text] [Related]
3. Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity.
Zhao C; Khadka DB; Cho WJ
Curr Med Chem; 2016; 23(13):1331-55. PubMed ID: 27048338
[TBL] [Abstract][Full Text] [Related]
4. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
5. Jak2: normal function and role in hematopoietic disorders.
Ihle JN; Gilliland DG
Curr Opin Genet Dev; 2007 Feb; 17(1):8-14. PubMed ID: 17208428
[TBL] [Abstract][Full Text] [Related]
6. Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling.
Ma X; Sayeski PP
Biochemistry; 2007 Jun; 46(24):7153-62. PubMed ID: 17530781
[TBL] [Abstract][Full Text] [Related]
7. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
[TBL] [Abstract][Full Text] [Related]
8. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
Fu LX; Lian QW; Pan JD; Xu ZL; Zhou TM; Ye B
J Biol Regul Homeost Agents; 2017; 31(1):51-58. PubMed ID: 28337870
[TBL] [Abstract][Full Text] [Related]
9. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
10. On the regulation and activation of JAK2: a novel hypothetical model.
Lee TS
Mol Cancer Res; 2013 Aug; 11(8):811-4. PubMed ID: 23615525
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH)-associated nitration of Janus kinase-2 at the 1007Y-1008Y epitope impedes phosphorylation at this site: mechanism for and impact of a GH, AKT, and nitric oxide synthase axis on GH signal transduction.
Elsasser TH; Li CJ; Caperna TJ; Kahl S; Schmidt WF
Endocrinology; 2007 Aug; 148(8):3792-802. PubMed ID: 17510232
[TBL] [Abstract][Full Text] [Related]
12. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
15. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
16. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
17. Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2*.
Schmalohr BF; Mustafa AM; Krämer OH; Imhof D
Chembiochem; 2021 Mar; 22(5):861-864. PubMed ID: 33103835
[TBL] [Abstract][Full Text] [Related]
18. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
19. Determinants of growth hormone receptor down-regulation.
Deng L; He K; Wang X; Yang N; Thangavel C; Jiang J; Fuchs SY; Frank SJ
Mol Endocrinol; 2007 Jul; 21(7):1537-51. PubMed ID: 17488973
[TBL] [Abstract][Full Text] [Related]
20. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
